A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely driven by strong demand in the United States.

Rising consumer demand for fewer empty calories is pushing the snack and beverage giant to offer options with less sodium, fat and artificial ingredients.